BioStar Capital

Nectero Medical is a clinical-stage biotechnology company based in Dover, Delaware, founded in 2017. The company is focused on developing a novel treatment aimed at stabilizing the growth of mid-sized abdominal aortic aneurysms and preventing their rupture. Nectero Medical's innovative approach involves delivering a compound with a stabilizing agent directly to the aneurysm site, which inhibits further breakdown of the vessel wall and strengthens it. This treatment enables patients to undergo earlier intervention safely, potentially delaying or eliminating the need for major endovascular or surgical repairs.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Amplitude Vascular Systems is a medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2020 and is based in Ann Arbor, Michigan.

Amplitude Vascular Systems is a medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2020 and is based in Ann Arbor, Michigan.

Amplitude Vascular Systems is a medical device company focused on safely and effectively treating severely calcified arterial disease. It was founded in 2020 and is based in Ann Arbor, Michigan.

REVA Medical, Inc. is a medical device company based in San Diego, California, established in 1998. The company specializes in developing and commercializing polymer-based bioresorbable products for vascular applications. Its primary offerings include the Fantom Encore, a bioresorbable vascular scaffold designed for the treatment of coronary artery disease, and the MOTIV scaffold for below-the-knee peripheral artery disease. REVA Medical's products utilize proprietary tyrosine-derived polymer technologies that support the healing of arteries while eventually dissolving in the body, thus restoring natural function. The Fantom Encore is marketed in several European countries, including Germany, Switzerland, and Italy. Initially founded as MD3, Inc., the company rebranded to REVA Medical, Inc. in March 2002.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Ablative Solutions, Inc. is a clinical-stage medical device company that specializes in the development of catheters for treating hypertension. Founded in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company offers the Peregrine System. This catheter facilitates the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. Ablative Solutions aims to provide an effective and safe alternative to traditional surgical renal denervation, utilizing an infusion catheter that performs chemical renal denervation with alcohol as the neurolytic agent. This approach is designed to offer significant advantages over energy-based systems, particularly for patients with hypertension that is not well controlled.

Foldax, Inc., established in 2013 and headquartered in Salt Lake City, Utah, specializes in the design and manufacture of synthetic heart valves. The company's primary product is the Tria biopolymer heart valve, which can be implanted percutaneously or surgically to treat aortic, mitral, or tricuspid valve disease. Foldax aims to provide non-thrombogenic valves at a significantly lower cost compared to existing artificial or tissue valves, reducing the need for lifelong anticoagulant drugs and their associated risks. The company operates in the manufacturing sector, focusing on life polymer technology to create durable and effective heart valve replacements.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, specializing in treatments for pulmonary arterial hypertension (PAH). Founded in 2010 by Drs. John Scandurra and Karl Vollmers, the company has developed an innovative implantable cardiovascular device aimed at reducing the workload on the right side of the heart. This device holds the potential to enhance both the survival and quality of life for patients suffering from pulmonary hypertension. Aria CV has secured an exclusive license for certain patents from the University of Minnesota, reflecting its commitment to advancing medical technology in this critical area of healthcare.

Corindus Vascular Robotics, Inc. specializes in the design, manufacture, and commercialization of robotic-assisted systems for interventional vascular procedures. Based in Waltham, Massachusetts, the company offers the CorPath system, which allows physicians to perform catheterization procedures from a radiation-shielded control console, enhancing precision and safety in coronary and peripheral interventions. The CorPath GRX system further enables the robotic-assisted control of guide catheters, guidewires, and balloon/stent devices. Corindus serves various markets, including vascular, coronary, neurointerventional, and structural heart fields, selling its products through a combination of direct sales and partnerships. Founded in 2002, Corindus is a subsidiary of Siemens Medical Solutions USA, Inc. as of late 2019.

Trice Medical, Inc. is a company that specializes in the development of innovative orthopedic diagnostic devices featuring integrated camera-enabled and needle-based technologies. Founded in 2011 and headquartered in Malvern, Pennsylvania, Trice Medical aims to enhance patient care by providing immediate and accurate diagnostic solutions that can be administered in a physician's office. Their products facilitate minimally invasive procedures that are designed to be painless, cosmetically undetectable, and of surgical grade quality. By optimizing the diagnostic process, Trice Medical seeks to eliminate inaccuracies associated with traditional indirect modalities, thereby reducing costs for the healthcare system while improving the overall patient experience.

Ablative Solutions, Inc. is a clinical-stage medical device company that specializes in the development of catheters for treating hypertension. Founded in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company offers the Peregrine System. This catheter facilitates the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. Ablative Solutions aims to provide an effective and safe alternative to traditional surgical renal denervation, utilizing an infusion catheter that performs chemical renal denervation with alcohol as the neurolytic agent. This approach is designed to offer significant advantages over energy-based systems, particularly for patients with hypertension that is not well controlled.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Corindus Vascular Robotics, Inc. specializes in the design, manufacture, and commercialization of robotic-assisted systems for interventional vascular procedures. Based in Waltham, Massachusetts, the company offers the CorPath system, which allows physicians to perform catheterization procedures from a radiation-shielded control console, enhancing precision and safety in coronary and peripheral interventions. The CorPath GRX system further enables the robotic-assisted control of guide catheters, guidewires, and balloon/stent devices. Corindus serves various markets, including vascular, coronary, neurointerventional, and structural heart fields, selling its products through a combination of direct sales and partnerships. Founded in 2002, Corindus is a subsidiary of Siemens Medical Solutions USA, Inc. as of late 2019.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, CathWorks aims to transform coronary angiography from subjective visual assessments into an objective decision-making tool. The company's flagship product, CathWorks FFRangio, is a non-invasive device that provides multi-vessel physiologic measurements, allowing physicians to optimize and confirm PCI therapy decisions during procedures. By leveraging functional flow reserve (FFR) data and automated algorithms, CathWorks enhances the use of coronary angiography data, promoting measurement-based medicine and improving operational efficiency in cath labs.

Trice Medical, Inc. is a company that specializes in the development of innovative orthopedic diagnostic devices featuring integrated camera-enabled and needle-based technologies. Founded in 2011 and headquartered in Malvern, Pennsylvania, Trice Medical aims to enhance patient care by providing immediate and accurate diagnostic solutions that can be administered in a physician's office. Their products facilitate minimally invasive procedures that are designed to be painless, cosmetically undetectable, and of surgical grade quality. By optimizing the diagnostic process, Trice Medical seeks to eliminate inaccuracies associated with traditional indirect modalities, thereby reducing costs for the healthcare system while improving the overall patient experience.

Corindus Vascular Robotics, Inc. specializes in the design, manufacture, and commercialization of robotic-assisted systems for interventional vascular procedures. Based in Waltham, Massachusetts, the company offers the CorPath system, which allows physicians to perform catheterization procedures from a radiation-shielded control console, enhancing precision and safety in coronary and peripheral interventions. The CorPath GRX system further enables the robotic-assisted control of guide catheters, guidewires, and balloon/stent devices. Corindus serves various markets, including vascular, coronary, neurointerventional, and structural heart fields, selling its products through a combination of direct sales and partnerships. Founded in 2002, Corindus is a subsidiary of Siemens Medical Solutions USA, Inc. as of late 2019.

TransMedics Group, Inc., established in 1998 and based in Andover, Massachusetts, is a commercial-stage medical technology company specializing in transforming organ transplant therapy for end-stage organ failure patients worldwide. The company's core product, the Organ Care System (OCS), is a portable, innovative technology that maintains donor organs outside the body in a near-physiologic state, replicating human-like conditions. This system includes OCS LUNG and OCS Heart, designed to preserve and optimize lungs and hearts respectively during transport, allowing for better assessment and improvement of organ condition. TransMedics also offers clinical services to enhance transplant volume, improve outcomes, and reduce learning curves for healthcare providers.

TransMedics Group, Inc., established in 1998 and based in Andover, Massachusetts, is a commercial-stage medical technology company specializing in transforming organ transplant therapy for end-stage organ failure patients worldwide. The company's core product, the Organ Care System (OCS), is a portable, innovative technology that maintains donor organs outside the body in a near-physiologic state, replicating human-like conditions. This system includes OCS LUNG and OCS Heart, designed to preserve and optimize lungs and hearts respectively during transport, allowing for better assessment and improvement of organ condition. TransMedics also offers clinical services to enhance transplant volume, improve outcomes, and reduce learning curves for healthcare providers.

V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

Kona Medical, Inc. is a medical technology company that specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Established in 2009 by Dr. Michael Gertner, the company focuses on addressing the challenges posed by drug-resistant hypertension through innovative approaches, particularly renal artery denervation. Its flagship product, Surround Sound, employs ultrasound imaging to precisely guide the delivery of focused ultrasound energy for renal denervation, offering a less invasive alternative to traditional treatments. Based in Issaquah, Washington, Kona Medical integrates Dr. Gertner's inventions with assets from Therus Corporation, enhancing its capabilities in therapeutic focused ultrasound.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, specializing in treatments for pulmonary arterial hypertension (PAH). Founded in 2010 by Drs. John Scandurra and Karl Vollmers, the company has developed an innovative implantable cardiovascular device aimed at reducing the workload on the right side of the heart. This device holds the potential to enhance both the survival and quality of life for patients suffering from pulmonary hypertension. Aria CV has secured an exclusive license for certain patents from the University of Minnesota, reflecting its commitment to advancing medical technology in this critical area of healthcare.

Trice Medical, Inc. is a company that specializes in the development of innovative orthopedic diagnostic devices featuring integrated camera-enabled and needle-based technologies. Founded in 2011 and headquartered in Malvern, Pennsylvania, Trice Medical aims to enhance patient care by providing immediate and accurate diagnostic solutions that can be administered in a physician's office. Their products facilitate minimally invasive procedures that are designed to be painless, cosmetically undetectable, and of surgical grade quality. By optimizing the diagnostic process, Trice Medical seeks to eliminate inaccuracies associated with traditional indirect modalities, thereby reducing costs for the healthcare system while improving the overall patient experience.

Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

VytronUS, Inc. is a manufacturer of cardiac medical devices, specializing in solutions for treating cardiac arrhythmia. Founded in 2006 and based in Sunnyvale, California, the company develops innovative technologies that leverage ultrasound energy for both imaging and therapeutic purposes. Its devices facilitate precise, non-contact energy delivery and create high-resolution maps of cardiac anatomy, empowering physicians to address complex arrhythmias with enhanced visualization and precision. VytronUS's focus on automation and flexibility in its device offerings positions it as a key player in the cardiac medical device market.

Trice Medical, Inc. is a company that specializes in the development of innovative orthopedic diagnostic devices featuring integrated camera-enabled and needle-based technologies. Founded in 2011 and headquartered in Malvern, Pennsylvania, Trice Medical aims to enhance patient care by providing immediate and accurate diagnostic solutions that can be administered in a physician's office. Their products facilitate minimally invasive procedures that are designed to be painless, cosmetically undetectable, and of surgical grade quality. By optimizing the diagnostic process, Trice Medical seeks to eliminate inaccuracies associated with traditional indirect modalities, thereby reducing costs for the healthcare system while improving the overall patient experience.

Domain Surgical is a medical device company that is creating energy-based surgical products for precise soft tissue cutting and coagulation. It creates energy-based equipment used in specialty surgical procedures. Its patent-pending technology produces surface-only tissue effects with energy that does not pass through the patient designed with the surgical staff in mind, for simple user-interface and training. The company manufactures and markets the FMwand Ferromagnetic Surgical System, a hemostatic dissection device that uses pure thermal energy to cut and coagulate soft tissue, without passing an electrical current through the patient. The FMwand imparts as little as 1/10th the amount of thermal injury compared to traditional electrosurgery devices. The FMwand provides fine dissection with a layer-by-layer precision that is unmatched by existing surgical technology.

Ablative Solutions, Inc. is a clinical-stage medical device company that specializes in the development of catheters for treating hypertension. Founded in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company offers the Peregrine System. This catheter facilitates the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. Ablative Solutions aims to provide an effective and safe alternative to traditional surgical renal denervation, utilizing an infusion catheter that performs chemical renal denervation with alcohol as the neurolytic agent. This approach is designed to offer significant advantages over energy-based systems, particularly for patients with hypertension that is not well controlled.

Trice Orthopedics, Inc., headquartered in King of Prussia, Pennsylvania, specializes in developing camera-enabled needle technology for orthopedic diagnostic and therapeutic procedures. The company aims to enhance the quality of patient care by facilitating instant and accurate office-based procedures. By integrating miniaturized opto-electronics into its clinical solutions, Trice's innovations provide more immediate and definitive results compared to traditional methods, which often yield false readings. This approach not only benefits patients and physicians by streamlining the diagnostic process but also aims to reduce healthcare costs through the utilization of existing reimbursement codes.

Trice Medical, Inc. is a company that specializes in the development of innovative orthopedic diagnostic devices featuring integrated camera-enabled and needle-based technologies. Founded in 2011 and headquartered in Malvern, Pennsylvania, Trice Medical aims to enhance patient care by providing immediate and accurate diagnostic solutions that can be administered in a physician's office. Their products facilitate minimally invasive procedures that are designed to be painless, cosmetically undetectable, and of surgical grade quality. By optimizing the diagnostic process, Trice Medical seeks to eliminate inaccuracies associated with traditional indirect modalities, thereby reducing costs for the healthcare system while improving the overall patient experience.

Angioslide, Ltd. is a medical device company established in 2005 and headquartered in Natanya, Israel, with additional subsidiaries in Karlsruhe, Germany, and Edina, Minnesota. The company specializes in developing innovative angioplasty products, notably the Angioslide eXtra balloon catheter, which serves both as a stand-alone balloon for angioplasty and as a device for debris removal. Its proprietary Embolic Capture Angioplasty™ technology allows physicians to capture and eliminate embolic particles, chronic thrombus, and atherosclerotic plaque debris during angioplasty procedures. Angioslide focuses on addressing the needs of various markets, including peripheral artery, lower limb artery, carotid, and coronary artery diseases.

Kona Medical, Inc. is a medical technology company that specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Established in 2009 by Dr. Michael Gertner, the company focuses on addressing the challenges posed by drug-resistant hypertension through innovative approaches, particularly renal artery denervation. Its flagship product, Surround Sound, employs ultrasound imaging to precisely guide the delivery of focused ultrasound energy for renal denervation, offering a less invasive alternative to traditional treatments. Based in Issaquah, Washington, Kona Medical integrates Dr. Gertner's inventions with assets from Therus Corporation, enhancing its capabilities in therapeutic focused ultrasound.

Ablative Solutions, Inc. is a clinical-stage medical device company that specializes in the development of catheters for treating hypertension. Founded in 2011 and headquartered in San Jose, California, with an additional office in Kalamazoo, Michigan, the company offers the Peregrine System. This catheter facilitates the minimally invasive delivery of diagnostic and therapeutic agents into the perivascular space surrounding peripheral blood vessels. Ablative Solutions aims to provide an effective and safe alternative to traditional surgical renal denervation, utilizing an infusion catheter that performs chemical renal denervation with alcohol as the neurolytic agent. This approach is designed to offer significant advantages over energy-based systems, particularly for patients with hypertension that is not well controlled.

Kona Medical, Inc. is a medical technology company that specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Established in 2009 by Dr. Michael Gertner, the company focuses on addressing the challenges posed by drug-resistant hypertension through innovative approaches, particularly renal artery denervation. Its flagship product, Surround Sound, employs ultrasound imaging to precisely guide the delivery of focused ultrasound energy for renal denervation, offering a less invasive alternative to traditional treatments. Based in Issaquah, Washington, Kona Medical integrates Dr. Gertner's inventions with assets from Therus Corporation, enhancing its capabilities in therapeutic focused ultrasound.

CV Ingenuity, a Palo Alto, CA-based medical device company. CV Ingenuity Corp., a medical device company, develops devices for the treatment of vascular diseases to relieve vascular obstructions, inhibit restenosis, and allow natural vessel healing. It offers Drug Coated Balloon platform for the "Touch-and-Go" treatment of vascular disease. It was incorporated in 2008 and is based in Fremont, California. As of January 10, 2013, CV Ingenuity Corp. operates as a subsidiary of Covidien plc.

Ellipse Technologies is a privately-held medical device company based in California that specializes in the development of implantable remote control technology for spinal and orthopedic applications. The company designs and commercializes innovative devices aimed at treating a wide range of spinal deformities and orthopedic trauma, including fracture management. Its flagship products, the MAGEC MAGnetic Expansion Control System and the PRECICE System, utilize advanced, non-invasive technologies that allow for remote adjustments by physicians through an external magnetic field. These devices are designed to restore proper anatomical position and alignment, improving patient outcomes in the management of spinal and long-bone abnormalities.

Reverse Medical is a commercial-stage medical device company dedicated to the development of innovative solutions for neurovascular disorders, particularly in the management of acute ischemic strokes. The company specializes in creating embolic protection systems designed to enhance the revascularization process for patients experiencing these critical conditions. By concentrating on endovascular treatment options, Reverse Medical aims to improve patient outcomes and streamline interventions for stroke care, positioning itself as a key player in the medical technology sector.

Embrella Cardiovascular, Inc. is a company based in Malvern, Pennsylvania, focused on developing innovative systems for embolic cerebral protection. Its primary goal is to assist interventionalists in minimizing the incidence of embolic strokes that can occur during cardiovascular procedures. By enhancing the safety and effectiveness of these interventions, Embrella Cardiovascular aims to improve patient outcomes and advance the field of cardiovascular medicine.

Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels.

SynergEyes, Inc. is a technology-driven company specializing in the development and manufacturing of hybrid contact lenses designed to enhance vision and improve quality of life for patients. Founded in 2001 and headquartered in Carlsbad, California, SynergEyes offers innovative products that combine the visual acuity of rigid gas permeable lenses with the comfort of soft lenses. Their hybrid lenses cater to a range of eye conditions, including astigmatism, presbyopia, myopia, hyperopia, and keratoconus, utilizing advanced high-Dk materials and vision-optimized designs. The company distributes its products both domestically and internationally, emphasizing a commitment to improving eye health and transforming vision for eye care professionals and their patients.

Corindus Vascular Robotics, Inc. specializes in the design, manufacture, and commercialization of robotic-assisted systems for interventional vascular procedures. Based in Waltham, Massachusetts, the company offers the CorPath system, which allows physicians to perform catheterization procedures from a radiation-shielded control console, enhancing precision and safety in coronary and peripheral interventions. The CorPath GRX system further enables the robotic-assisted control of guide catheters, guidewires, and balloon/stent devices. Corindus serves various markets, including vascular, coronary, neurointerventional, and structural heart fields, selling its products through a combination of direct sales and partnerships. Founded in 2002, Corindus is a subsidiary of Siemens Medical Solutions USA, Inc. as of late 2019.

AorTx, Inc. develops device solutions for percutaneous replacement of the aortic valve in the United States. Its devices cover the procedural solution for heart valve therapy from the implant to delivery and deployment of the valve. AorTx, Inc. was formerly known as CardiacMD, Inc. The company is based in Redwood City, California. As of November 15, 2007, AorTx, Inc. operates as a subsidiary of Hansen Medical, Inc.

Avantis Medical Systems, Inc. is a medical device company based in Sunnyvale, California, focused on developing and manufacturing catheter-based endoscopic devices. The company aims to enhance the detection and treatment of cancers and other abnormalities within the gastrointestinal (GI) tract. Leveraging decades of experience in the medical device industry, Avantis is creating innovative solutions that integrate advanced technologies, such as micro-chips and reinforced catheters. Their offerings are designed to provide safe, effective, and cost-efficient healthcare services, ultimately enhancing patient outcomes and recovery times.

Pynk is an investment platform that harnesses the power of Artificial Intelligence to leverage the Wisdom IN Crowds™, allowing users to make informed investment decisions. The company aggregates predictions and forecasts from a global community of contributors across more than 185 countries, utilizing machine learning to analyze market data effectively. Founded in 2018 by experienced entrepreneurs Seth Ward, Rupert Barksfield, and Mark Little, Pynk aims to democratize wealth management by combining crowd-sourced insights with expert analysis. The platform empowers investors to mitigate risks and potentially achieve superior returns. Pynk is supported by notable financial institutions, including RBS and Natwest banks in the UK, and has successfully raised $2 million in pre-seed and seed funding to date.

Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, including emphysema and lung cancer. Based in Mountain View, California, with an international presence in Nyon, Switzerland, Broncus is focused on addressing significant unmet medical needs in interventional pulmonology. The company is exploring its Exhale product line, which features a patented treatment method known as Airway Bypass, aimed at providing a minimally-invasive solution for patients suffering from homogeneous emphysema. Broncus is currently conducting the pivotal EASE Trial, enrolling patients worldwide to evaluate the efficacy of this treatment in severe cases of the disease. Additionally, Broncus offers a range of innovative products designed to enhance diagnostic and therapeutic outcomes in lung care, including the Archimedes System, LungPoint, and InterVapor System.

Avantis Medical Systems, Inc. is a medical device company based in Sunnyvale, California, focused on developing and manufacturing catheter-based endoscopic devices. The company aims to enhance the detection and treatment of cancers and other abnormalities within the gastrointestinal (GI) tract. Leveraging decades of experience in the medical device industry, Avantis is creating innovative solutions that integrate advanced technologies, such as micro-chips and reinforced catheters. Their offerings are designed to provide safe, effective, and cost-efficient healthcare services, ultimately enhancing patient outcomes and recovery times.